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Abstract
Aim: In colorectal cancer (CRC), adjuvant therapy is offered on the basis of stage and attempts to identify
factors to better target treatment have not been successful. Recent work suggested that mismatch repair
deficient CRCs may not benefit from 5FU adjuvant chemotherapy but studies remain conflicting. We aimed
to determine if gender, tumor site, tumor pathological characteristics and microsatellite instability (MSI)
predict survival benefit from adjuvant chemotherapy in stage C CRC.
Methods: Data were collated on ACPS (Australian Clinico-pathological Staging System) stage C CRC cases
that underwent curative resection over a 23-year period. Pathologywas reevaluated, DNAwas extracted from
the formalin-fixed paraffin specimen, and MSI status was established by BAT26 instability. Multivariate
analysis was performed using Cox proportional hazard model and effects modification interaction testing.
Results: In total 814 unselected cases were included, of whom 37% received chemotherapy. Seventy-seven
cases exhibited MSI. Overall, adjuvant chemotherapy produced a cancer-specific survival benefit (HR 0.52,
95% CI 0.39–0.70; P < 0.0001). On interaction testing, none of the examined parameters significantly
influenced the magnitude of that survival benefit. Chemotherapy was beneficial in both the MSI (HR 0.08,
95% CI 0.02–0.27; P = < 0.0001) and the microsatellite stable cohort (HR 0.62, 95% CI 0.47–0.81;
P = 0.001).
Conclusion: These results suggest that survival benefit from 5FU adjuvant chemotherapy for stage C CRC
does not vary according to gender, site of tumor, pathological characteristics or MSI status. This study
suggests that it would be unwise to exclude patients from being offered adjuvant chemotherapy on the basis
of MSI.
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INTRODUCTION
Much recent emphasis in cancer treatment has been
toward individualizing cancers and better targeting
treatment. In colorectal cancer (CRC), the decision for
adjuvant chemotherapy is still based largely on tumor
stage. Attempts to stratify risk within heterogeneous
stage groups have not produced clinically useful results
and identification of factors to target treatment has
proven elusive.
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It has been suggested that female gender and patients
with proximal colonic tumors may receive greater
benefit from adjuvant chemotherapy.1 However, this
advantage is not marked. It is also often assumed that
poor prognostic stage C tumors will have a greater
benefit from adjuvant chemotherapy but evidence for
this is lacking.
In an attempt to understand which patients may
derive greater benefit from adjuvant chemotherapy,
recent work has focused on tumors with microsatellite
instability (MSI), being indicative of tumors with defi-
ciency of a mismatch repair (MMR) protein. Initial in
vitro work predicted resistance in MSI tumors.2–4 In
contrast, early clinical studies suggested a trend to
improved survival for MSI cases given 5-fluorouracil
(5FU) adjuvant chemotherapy,1,5–7 including the sugges-
tion that they would be the only ones to benefit.1 Other
studies have shown no difference in the survival benefit
between MSI high and microsatellite stable (MSS)
tumors,8,9 while others suggest the MSI cases are not
benefitting.10–16 Furthermore, some studies have sug-
gested there may be a negative impact on survival in
MSI tumors.12,14
The aim of this study was to determine if gender,
tumor site, tumor pathological characteristics and MSI
status could predict survival benefit from 5FU-based
adjuvant chemotherapy given post curative resection for
node-positive CRC.
METHOD
This study is a retrospective cohort study, comparing
survival in patients who received chemotherapy with
those who did not, looking for a compounding effect
from clinical and pathological parameters and MSI
status. Patients were eligible if they underwent a curative
resection for an ACPS (Australian Clinico-pathological
Staging System) stage C17 colon or rectal adenocarci-
noma (equivalent to AJCC stage C). All identifiable
cases from three hospitals over a 23-year period were
included (1980–2003). Cases from years prior to the use
of standard chemotherapy in our institutions were
included to minimize the selection bias in the non-
chemotherapy cohort. Cases were excluded if death
occurred perioperatively or if non-CRC cancers were
present. Cases of multiple CRC were included only if an
index stage C cancer could be clearly established; syn-
chronous cancers were included if the second cancer was
clearly an earlier stage and metachronous cancers were
included if the previous cancer occurred more than 5
years beforehand. Only patients who received single
agent 5FU-based regimens were included. This included
infusional and bolus 5FU (±folinic acid). Patients who
received combination therapy (i.e. with oxaliplatin)
were excluded. Cases were classified by intention to
treat – if the patient at least commenced treatment, the
case was included in the chemotherapy cohort. Admin-
istration of radiotherapy was recorded. Appropriate
ethics approval was obtained from the hospitals’ human
research ethics committees. Cases were identified from
hospital and state registries and pathology databases.
Demographic and operative data were collated and case
notes were reviewed if required. Death data were
sourced from the South Australian State Cancer Regis-
try, which is cross-checked regularly with national
databases.18
Tumor site was determined from operative report
and proximal tumors were defined as including the
splenic flexure. Obstruction and perforation were
assessed from the pathological specimen. Pathology
reports and archived slides for all cases were retrieved.
A single specialist colorectal pathologist (ARR)
reevaluated all pathological slides. If slides were
inadequate or lost, further sections were taken from
archived tissue blocks. Negative margins were
confirmed.
MSI analysis
MSI was established by identification of instability in the
mononucleotide sequences BAT 40 and BAT 26, the
latter being highly specific for MSI high.19 Tumor and
normal DNA samples were taken from formalin-fixed
paraffin embedded archived specimens. Tissue was
dewaxed and DNA was extracted using Tris/EDTA
DNA buffer and proteinase K, 6 M NaCl for salt extrac-
tion, and ethanol. One of the microsatellite primer pairs
was fluorescently 5′-labeled during synthesis. DNA
(2.5–10 ng) was amplified in a standard 50 μL reaction
mix: 200 μM of each dNTP, 2 mM of MgCl, 0.2 μM of
forward fluorescent and reverse non-labeled primers,
0.5 U of AmpliTaq Gold DNA (Perkin-Elmer/Cetus,
Waltham, Massachusetts, USA). Cycling conditions
involved an initial denaturation at 95°C, 30 s at 55°C
and 90 s at 68°C with a final extension of 10 min at
68°C. PCR products of paired normal and tumor tissue
were electrophoresed using an ABI Prism 377 or 3700
DNA sequencer (Perkin-Elmer) and analyzed using
Gene scan and Genotyper (Applied Biosystems, Carls-
bad, California, USA). The complete National Cancer
Institute (NCI) panel20 was run on equivocal cases
including when there was discordance between the BAT
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26 and BAT 40 result, MSI defined by instability in two
or more markers.
MSI status was categorized as positive or negative.
“Positive” in this study is equivalent to MSI high (given
the specificity of the markers used). Patients with an
equivocal NCI panel result were classified as negative.
Statistical analysis
The primary study endpoint was cancer-specific sur-
vival. Noncancer deaths were censored. Univariate
analysis was performed using Kaplan–Meier survival
curves and compared by log rank test. A Cox regression
proportional hazard model was used for multivariate
analysis with backward elimination by likelihood ratio.
Significance was set at 0.05 and confidence intervals
at 95%. Interaction testing was incorporated into the
adjusted analysis model to test for effects modification.
Chi-square testing was used to compare groups. Analy-
sis was performed using PASW Statistics for Windows
(version 18, Copyright 2009, SPSS Inc, Chicago, IL,
USA) and Intercooled Stata for Windows (version 8.2,
Copyright 2004, StataCorp LP, College Station, Texas,
USA).The association between MSI and pathological
factors was tested by logistic regression. A priori power
calculations determined that 372 patients were required
per group to achieve 80% power to show a 10% sur-
vival difference between groups (chemotherapy vs no
chemotherapy).
RESULTS
Over the 23-year study period, 993 ACPS stage C cases
were identified that had undergone a curative resection.
Of these, 179 cases were excluded, 128 because pathol-
ogy was unavailable, 42 died in hospital perioperatively,
7 had multiple CRCs that met the exclusion criteria, and
in 2 cases there was inadequate clinical information.
This left 814 cases for study. Cases were near consecu-
tive apart from the first 5-year period when not all
cancers were registered in the available databases.
Twelve specimens could not be assessed for MSI due to
lack of tissue and were not included in the MSI analysis.
Three cases with synchronous CRCs were not included
in the site analysis. Median follow-up was 36.3 months
overall (range 0.6–290 months) and 72 months (6 years)
for living patients. Median age was 71 years (range
30–96 years). Gender distribution was equal (male
49.6%, female 50.4% ns). Sixty-one percent of tumors
were located distal to the splenic flexure. The pathologi-
cal data frequency and prognostic influence are shown
in Table 1.
Of the 802 cases where MSI status was successfully
established, 9.6% (77) were positive. Of these, 27
(35%) received chemotherapy. MSI cases were more
likely to be women (70% compared with 48% of MSS
cancers, P < 0.0001) and the tumors were more likely to
be proximal (83% compared with 40%, P < 0.0001)
(Table 2), although on adjusted analysis only proximal
site remained significant (HR of MSI in a distal cancer
was 0.16, 95% CI 0.08–0.33; P < 0.0001). They were
more likely to be poorly differentiated (83% vs 35%,
P < 0.0001) and there was a strong association with
tumor infiltrating lymphocytes found in 30% of MSI
cases, but only 1.5% of MSS cases (P < 0.0001).
Gender or tumor site did not affect outcome on uni-
variate or multivariate analysis. Perforation but not
obstruction had an adverse effect on survival (HR 2.27,
95% CI 1.46–3.53; P < 0.0001). The pathological
parameters that were associated with a significantly
poorer survival were higher nodal stage, poor differen-
tiation, mucinous component to the tumor, extramural
vascular invasion and perineural invasion (Table 1). T
stage, tumor size, nature of advancing edge (infiltrative
or pushing), type of stroma and budding did not inde-
pendently influence survival. MSI status did not signifi-
cantly affect survival across the whole group but was
associated with a better prognosis in the untreated
cohort (HR 1.98, 95% CI 1.23–3.20; P = 0.005).
Chemotherapy was commenced in 37% of patients
and radiotherapy in 12%. Cases prior to 1993 (the year
of implementation of standard adjuvant chemotherapy
in our institutions) comprised half of the non-
chemotherapy cohort. The chemotherapy cohort was
younger (65.4 years vs 75.1 years, P < 0.0001), had a
slight male predominance (56.0% vs 45.8%, P = 0.005)
and had a higher proportion of poor prognostic indica-
tors (Table 3). Overall, 469 (57.6%) patients died
during the study period. Of these, 76% were CRC-
related deaths.
Chemotherapy significantly improved outcome.
Adjusting for all other variables, the hazard ratio of
dying of cancer if chemotherapy was given was 0.52
(95% CI 0.39–0.70; P < 0.0001). Five-year cancer-
specific survival was 58% compared with 40% in the
non-chemotherapy cohort (P < 0.0001). Gender, site
and combination subgroups using these parameters all
showed significant benefit from adjuvant treatment
(men/proximal given chemotherapy HR cancer death
0.47 [95% CI 0.25–0.87, P = 0.02], men/distal 0.61
[0.69–0.97, P = 0.04], women/proximal 0.43 [0.24–
0.78, P = 0.005], women/distal 0.40 (0.24–0.68,
P = 0.001). There was a trend to less effect in men
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especially for distal tumors, but on interaction testing
gender or tumor site did not influence the magnitude of
the survival benefit from adjuvant chemotherapy. On
interaction testing, no individual pathological factor
was significantly associated with a greater benefit from
chemotherapy.
When chemotherapy effect was tested in the MSI and
MSS cohorts, both derived a significant benefit from
treatment (Fig. 1). Five-year cancer-specific survival
results show the significant benefit in MSI cases (76%
vs 43%, P = 0.009) and MSS cases (59% vs 52%,
P = 0.005). Adjusted analysis is shown in Table 4. Che-
motherapy improved survival in both the MSI cases (HR
0.08, 95% CI 0.02–0.27; P = < 0.0001) and the MSS
cases (HR 0.62, 95% CI 0.47–0.81; P = 0.001). While
the hazard ratio of dying in the MSI group was mark-
edly decreased by chemotherapy, seemingly much more
than the MSS group, effect modification interaction
testing did not reach significance (0.08). Thus, the mag-
nitude of the survival benefit from chemotherapy was
not significantly influenced by MSI status.
DISCUSSION
It is well recognized that there is survival advantage
from adjuvant chemotherapy in node-positive CRC, but
it is equally recognized that a significant number of
patients are being overtreated because they are either
cured by surgery alone or have disease that is not
curable with chemotherapy.21–23 Accordingly, there is
great interest in trying to predict which patients derive
benefit from adjuvant chemotherapy following appar-
ently curative resection of CRC.
This study is one of the larger to examine gender,
tumor site and pathological factors that might differen-
tially influence response to adjuvant chemotherapy. Our
results show that neither gender nor tumor site (or
in combination) influenced the survival benefit from
Table 1 Frequency of pathology parameters and hazard ratio of cancer death for factors associated with poorer prognosis
Overall Subcategory n % HR 95% CI P
T stage 1/2 65 8.0% ns
3/4 743 92.0%
NA 3
N stage 1 577 71.1%
2 234 28.9% 2.11 1.67–2.66 <0.0001
Differentiation Well/Moderate 667 82.2%
Poor 143 17.6% 1.40 1.05–1.87 0.02
NA 1 0.1%
Mucinous component Present 314 39.3% 1.29 1.02–1.63 0.03
Vascular invasion Mural 558 68.6%
Extramural 453 55.8% 1.78 1.37–2.31 <0.0001
Perineural invasion Present 142 17.5% 1.45 1.10–1.91 0.01
Advancing edge Infiltrative 256 31.6% ns
Pushing 550 67.8%
NA 5 0.6%
Budding Present 314 38.7% ns
Absent 492 60.7%
NA 5 0.6%








Obstruction 129 15.8% ns
Perforation 30 3.7% 2.27 1.46–3.53 <0.0001
811 cases as 3 cases had synchronous cancers so were not included in the adjusted analysis which included tumor site. †More than one type may be
present. NA, not assessable due to radiotherapy effect; TIL, tumor infiltrating lymphocyte.
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adjuvant chemotherapy. Subgroup analyses in the early
chemotherapy trials failed to show significant gender
variation in chemotherapy responsiveness.21–23 This was
supported by Gill et al. in their reanalysis of seven
adjuvant chemotherapy randomized controlled trials
(RCTs).24 In contrast, in their study of 656 stage C cases,
Elsaleh et al. showed that proximal cancers and women
(and in combination) had the greatest benefit from adju-
vant chemotherapy while men with distal lesion did not
derive benefit.1 We showed a similar trend; however,
men with distal lesions did still have a significant benefit
from chemotherapy.
While it is well recognized that the histological fea-
tures of CRCs have a prognostic effect, none of the
factors we investigated were shown to predict the effect
of chemotherapy. This is supported by Gill et al. who
found that neither T stage, N stage, nor grade influenced
the effect of chemotherapy in stage B and C colon
cancers.24 This suggests that none of the histological
factors we investigated could be used to target treatment.
We found that both MSI and MSS cancer groups
derived a survival benefit from 5FU-based chemo-
therapy, and that the effect was not significantly greater
in one or the other. The views in the literature on pre-
dictive value of MSI status on chemotherapy effect have
been quite disparate. Some of the earlier studies sug-
gested that there was greater chemotherapy benefit in
MSI-high cases when these cases were shown to do well
with treatment.5,7,10 However, this may have only high-
lighted the better prognosis often observed in MSI
cases.6,25,26 In 2001, Elsaleh et al. showed that MSI-
positive cases (8.5% of 656 stage C CRC cases) had a
marked improvement in 5-year survival with 5FU
chemotherapy (37% without treatment vs 90% with
Table 2 MSI/MSS cohort comparison
MSI (77) MSS (725)
Pn % n %
Median age 72.8 70.7 0.02
Gender Male 23 29.9% 375 51.7% <0.0001
Female 54 70.1% 350 48.3%
Proximal 64 83.1% 250 34.6% <0.0001
Median size 53 mm 40 mm <0.0001
T stage 1/2 0 65 8.0%
3/4 77 100% 654 90.2%
NA 6
N stage 1 55 71.4% 516 71.2%
2 22 28.6% 209 28.8%
Differentiation Moderate 34 44.2% 623 86.4% <0.0001
Poor 43 55.8% 98 13.6%
NA 4
Mucinous component Present 53 68.8% 257 35.4% <0.0001
Vascular invasion Mural 46 59.7% 506 70.3% 0.06
Extramural 42 54.5% 403 56.0% 0.81
Perineural invasion Present 7 9.1% 134 18.7% 0.04
Infiltrating advancing edge 12 15.6% 241 33.6% 0.001
Budding 13 16.9% 298 41.5% <0.0001
Stroma Fibroid 55 71.4% 472 65.8% 0.51
Keloid 21 27.3% 238 33.2%
Myxoid 1 1.3% 7 1.0%
NA 8
Lymphocytes† Peritumoral 69 89.6% 606 84.5% 0.23
Crohn’s 32 41.6% 141 19.6% <0.0001
TILs 24 31.2% 11 1.5% <0.0001
Obstructed 13 17.1% 112 15.6% 0.7
Perforated 2 2.7% 28 3.9% 0.59
802 cases as MSI was unable to be established in 12 cases. †More than one type may be present. NA, not assessable due to radiotherapy effect; TIL,
tumor infiltrating lymphocyte.
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chemotherapy) whereas MSS cases did not benefit at all
(32% vs 35%) . While this part of the analysis was
unadjusted and groups were not matched, the findings
were striking.
However in 2003, Ribic et al. published results that
were contradictory.12 Five hundred and seventy stage 2
and 3 colon cancer cases were included from five past
randomized 5FU adjuvant chemotherapy trials. The
5-year overall survival for MSI cases without treatment
was 75.5% while with treatment was only 70.7%,
although this did not reach significance (P = 0.07). In
contrast, the MSS cases showed improved survival from
68.4 to 88% with chemotherapy (P = 0.02). Interest-
ingly on adjusted analysis, no significant chemotherapy
benefit was observed across the whole patient group but
a trend to better outcome in the stage C group with
treatment (HR 0.69, CI 0.47–1.01). There was a non-
significant trend to a worse outcome in MSI cases given
chemotherapy (HR of dying 2.14, 95% CI 0.83–5.49
ns) and interaction testing showed that MSI status influ-
enced the effect of adjuvant chemotherapy (P = 0.01).
They suggested chemotherapy may be detrimental in
MSI cases.
This study group was expanded in 2010 by Sargent
et al. to include a further 457 cases again from past
randomized trials and mismatch repair protein (MMR)
status was established by either MSI testing or lack of
MMR protein on immunohistochemistry.14 Multivariate
analysis of the pooled data (1027 cases, adjusted for
stage, age and sex) showed that only the stage 3 MMR
proficient cases had a survival advantage from chemo-
therapy. In the MMR deficient group, there was no
survival benefit from chemotherapy. In the stage 2MMR
deficient cases, the overall survival was worsened by
chemotherapy (HR 2.95, 95% CI 1.02–8.54; P = 0.04).
No detrimental effect was observed in the stage 3 cases.
Table 3 Chemotherapy cohort matching
Subgroup Category Chemo (307) % No chemo (507) % P-value
Median age 65.4 years 75.1 years <0.0001
Gender Male 172 56.0% 232 45.8% 0.005
Female 135 44.0% 275 54.2%
Site† Proximal 114 37.3% 204 40.4% 0.37
Distal 192 62.7% 301 59.6%
T stage T1/2 25 8.2% 40 8.0% 0.90
T3/4 280 91.8% 463 92.0%
NA 2 4
N stage N1 204 66.4% 376 74.2% 0.02
N2 103 33.6% 131 25.8%
Differentiation Moderate 258 84.3% 409 81.2% 0.25
Poor 48 15.7% 95 18.8%
NA 1 3
Mucinous component Present 119 39.4% 195 39.3% 0.98
Vascular invasion Mural 223 73.4% 335 66.5% 0.04
Extramural 184 60.3% 269 53.4% 0.05
Perineural Present 59 19.5% 83 16.6% 0.30
Advancing edge Infiltrating 105 34.7% 151 30.0% 0.17
Budding Present 118 38.9% 196 39.0% 0.99
Stroma Fibroid 194 64.0% 342 68.0% 0.14
Keloid 108 35.6% 154 30.6%
Myxoid 1 0.3% 7 1.4%
NA 4 4
Lymphocytes Peritumoral 283 93.7% 402 79.9% 0.0001
Crohn’s 69 22.8% 106 21.0% 0.53
TILs 12 3.9% 23 4.6% 0.68
Obstructed 43 14.1% 86 17.2% 0.26
Perforated 11 3.6% 19 3.8% 0.89
MSI positive 27 9.0% 50 10.0% 0.66
†Three cases of synchronous tumors not included in site analysis. NA, not assessable due to radiotherapy effect; TIL, tumor infiltrating lymphocyte.
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This finding, that there was no benefit from chemo-
therapy in MSI cases, was supported by two subsequent
studies13,15 and many clinicians reconsidered their prac-
tice and became disinclined to give 5FU adjuvant che-
motherapy to MSI cases. However, there have been
more recent studies that challenge the appropriateness
of this approach and show that MSI status does not
influence adjuvant chemotherapy benefit. Reanalyses of
patients from both the National Surgical Adjuvant
Breast and Bowel Project (NSABP) and QUASAR trial
found that MSI status did not affect chemotherapy
responsiveness.8,9 Interestingly, in their analysis of 2141
cases from various past adjuvant chemotherapy RCTs
(inclusive of trial patients from the Ribic and Sargent
studies), Sinicrope et al. found that overall stage 3
MMR deficient cases did benefit from 5FU-based adju-
vant therapy, although it was limited to the cases they
identified as likely germline rather than sporadic (loss of
MSH2 protein or less than 55 years at time of treatment
with loss of MLH1 protein and/or MSI high).16
The current study has limitations. We did not use
randomized data but in an attempt to overcome this we
comprehensively adjusted for prognostic influences. We
drew as many cases as possible from the time before the
standard use of adjuvant chemotherapy to minimize
selection bias. There were slightly more cancers with
(a) (b)
Figure 1 (a) Chemotherapy effect in MSS cases. (b) Chemotherapy effect in MSI-positive cases. Chemotherapy: , no; , yes;
, no – censored; , yes – censored.
Table 4 Multivariate analysis of adjuvant chemotherapy effect according to MSI
HR of dying 95% CI P
Chemotherapy effect All patients 0.52 0.39–0.70 <0.0001
For MSS cases 0.62 0.47–0.81 0.001
For MSI cases 0.08 0.02–0.27 <0.0001
Multivariate analysis adjusted for age, gender, site (proximal/distal) and pathological factors as per Table 1. Cancer-specific survival.
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poor prognostic factors in the chemotherapy group, but
this would only have diminished the improved survival
we observed with chemotherapy. Despite having reason-
able numbers, the current study was underpowered to
show subtle differences. This was partly due to the low
percentage of MSI-positive cases. Our frequency of
9.6% is not dissimilar to other studies of stage C disease
where MSI was found in around 10% of cases,1,25 less
than the 15% cited overall for CRC.27–30 We analyzed
BAT 26 and 40 to determine MSI status, performing the
entire NCI panel20 only on equivocal cases, but this
should not have underestimated the frequency given the
sensitivity of BAT26 for MSI high is close to 99%.19,31,32
The included data are robust. All pathology was reex-
amined to ensure the accuracy and consistency of histo-
logical factors and allowed for inclusion of more
recently recognized histological factors. Data for this
study were gathered from several prospective databases,
including the South Australian Cancer Registry that is
dedicated to the accurate and thorough collation of
cancer data.18 Inaccuracies relating to retrospective
review of data were minimized by extensive cross-
checking. Certain factors were not included if accuracy
could not be assured, such as patient comorbidities.
While this factor may have influenced whether chemo-
therapy was given, we attempted to minimize its influ-
ence by studying cancer-specific survival.
There is not an obvious reason why our findings
should vary from the Ribic and Sargent studies. We
included rectums and only stage C cases but the trends
they observed persisted on stage subgrouping. We did
not use randomized data but adjusted more extensively
for covariates that may have influenced outcome. The
patient groups were similar except for age. The median
age in our study was older than those in the Ribic study
(71 vs 59.8 years) but our findings did not vary even on
exclusion of older patients (data not included) and we
used cancer-specific survival rather than their overall
survival. The different methods of establishing MMR
deficiency should not have influenced results given the
high concordance between detecting MMR deficiency
by lack of the protein on immunohistochemistry and
establishment of MSI high on molecular testing.19
In conclusion, this study showed that patient gender,
tumor site, pathological tumor characteristic and MSI
status did not influence the benefit observed from 5FU
adjuvant chemotherapy and, at least in this patient
group, none of these factors could have been used to
target treatment. While the use of adjuvant chemo-
therapy in microsatellite unstable cancer cases has been
questioned, there remains significant controversy and
there is now sufficient conflicting evidence to question
the emerging dogma that MSI cases do not benefit from
5FU chemotherapy. The contrary studies show a lack of
benefit at worst, not a significant detrimental effect in
the stage C cases. In our group, if chemotherapy had not
been offered on the basis of MSI, there would have been
a significantly worse outcome, given 57% of MSI cases
who did not get chemotherapy died from their cancer
within 5 years compared with only 24% of those who
received treatment. It is likely that further studies of MSI
alone as a predictive biomarker will be unhelpful and
continue to produce contradictory results, but it may be
that study of related biomarkers such as Braf will be
useful. Given the findings of the current study and the
remaining controversy, it would be unwise not to offer
MSI-high cases adjuvant chemotherapy.
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